Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.
Vincenzi B, Santini D, Perrone G, Graziano F, Loupakis F, Schiavon G, Frezza AM, Ruzzo AM, Rizzo S, Crucitti P, Galluzzo S, Zoccoli A, Rabitti C, Muda AO, Russo A, Falcone A, Tonini G. Vincenzi B, et al. Among authors: galluzzo s. J Cell Physiol. 2012 Mar;227(3):927-33. doi: 10.1002/jcp.22801. J Cell Physiol. 2012. PMID: 21503888
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.
Vincenzi B, Galluzzo S, Santini D, Rocci L, Loupakis F, Correale P, Addeo R, Zoccoli A, Napolitano A, Graziano F, Ruzzo A, Falcone A, Francini G, Dicuonzo G, Tonini G. Vincenzi B, et al. Among authors: galluzzo s. Ann Oncol. 2011 May;22(5):1141-1146. doi: 10.1093/annonc/mdq550. Epub 2010 Nov 29. Ann Oncol. 2011. PMID: 21115601 Free article.
Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome.
Vincenzi B, Santini D, Galluzzo S, Russo A, Fulfaro F, Silletta M, Battistoni F, Rocci L, Zobel BB, Adamo V, Dicuonzo G, Tonini G. Vincenzi B, et al. Among authors: galluzzo s. Clin Cancer Res. 2008 Jul 1;14(13):4219-24. doi: 10.1158/1078-0432.CCR-08-0077. Clin Cancer Res. 2008. PMID: 18594003 Free article.
Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.
Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, Schiavon G, Angeletti S, Uzzalli F, Caraglia M, Dicuonzo G, Tonini G. Santini D, et al. Among authors: galluzzo s. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4482-6. doi: 10.1158/1078-0432.CCR-07-0551. Clin Cancer Res. 2007. PMID: 17671133
Are bisphosphonates the suitable anticancer drugs for the elderly?
Santini D, Fratto ME, Galluzzo S, Vincenzi B, Tonini G. Santini D, et al. Among authors: galluzzo s. Crit Rev Oncol Hematol. 2009 Jan;69(1):83-94. doi: 10.1016/j.critrevonc.2008.07.008. Epub 2008 Aug 8. Crit Rev Oncol Hematol. 2009. PMID: 18692400 Review.
Cetuximab: from bench to bedside.
Vincenzi B, Zoccoli A, Pantano F, Venditti O, Galluzzo S. Vincenzi B, et al. Among authors: galluzzo s. Curr Cancer Drug Targets. 2010 Feb;10(1):80-95. doi: 10.2174/156800910790980241. Curr Cancer Drug Targets. 2010. PMID: 20088790 Review.
Targeting EGFR in bilio-pancreatic and liver carcinoma.
Fratto ME, Santini D, Vincenzi B, Silvestris N, Azzariti A, Tommasi S, Zoccoli A, Galluzzo S, Maiello E, Colucci G, Tonini G. Fratto ME, et al. Among authors: galluzzo s. Front Biosci (Schol Ed). 2011 Jan 1;3(1):16-22. doi: 10.2741/s128. Front Biosci (Schol Ed). 2011. PMID: 21196353 Free article. Review.
Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients.
Santini D, Vincenzi B, Adamo V, Addeo R, Fusco V, Russo A, Montemurro F, Roato I, Redana S, Lanzetta G, Satolli MA, Berruti A, Leoni V, Galluzzo S, Antimi M, Ferraro G, Rossi M, Del Prete S, Valerio MR, Marra M, Caraglia M, Tonini G. Santini D, et al. Among authors: galluzzo s. Oncol Rep. 2011 Jun;25(6):1545-8. doi: 10.3892/or.2011.1235. Epub 2011 Mar 28. Oncol Rep. 2011. PMID: 21455582 Free article.
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients.
Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, La Verde N, Caroti C, Treilleux I, Ruggiero A, Perrone G, Addeo R, Clezardin P, Muda AO, Tonini G. Santini D, et al. Among authors: galluzzo s. PLoS One. 2011 Apr 29;6(4):e19234. doi: 10.1371/journal.pone.0019234. PLoS One. 2011. PMID: 21559440 Free PMC article.
New developments of aminobisphosphonates: the double face of Janus.
Santini D, Galluzzo S, Vincenzi B, Schiavon G, Fratto E, Pantano F, Tonini G. Santini D, et al. Among authors: galluzzo s. Ann Oncol. 2007 Jun;18 Suppl 6:vi164-7. doi: 10.1093/annonc/mdm249. Ann Oncol. 2007. PMID: 17591815 Free article. Review.
59 results